1. Challenging the Myths in Heart Failure With Reduced Ejection Fraction

3. Myth #1: My HFrEF Patient Is Stable and Is Out of Danger

4. Other Questions to Consider……

5. Myth #2: We Should Start Low and Go Slow With Drug Uptitrations

6. ATLAS Trial: Dose Response in HF

7. Considerations for Uptitration in HFrEF

8. Uptitration of HF Therapies How Do We Overcome the Delays?

9. Reasons Drug Uptititration Does Not Occur

10. What are the Goals for Uptitration?

11. Myth #3: My HFrEF Patient Does Not Need an MRA

12. ESC Guidelines for Chronic HF

13. ESC HF Long-Term Registry Use of Pharmacological Therapies

14. MRAs in HF

15. MRA Use in the Elderly

16. Ontario Study: Hyperkalemia With MRAs

17. Myth #4: My HFrEF Patient Does Not Need an ARNI

18. PARADIGM-HF: Cardiovascular Death or Heart Failure Hospitalization (Primary Endpoint)

19. ACE Inhibitor vs ARNI

20. PARADIGM HF: Adverse Events With Sacubitril/Valsartan

21. PARADIGM-HF: Angioedema

22. Sacubitril/Valsartan in HFrEF: Starting Dose and Dose Titration

23. Myth #5: My HFrEF Patient Has Multiple Comorbidities and HF in This Context Is Very Difficult to Manage

24. COPD and Heart Failure

25. Atrial Fibrillation and HF

26. Diabetes and Heart Failure

27. Abbreviations

28. Abbreviations (cont)